Dimerix Limited · ASX:DXB
Dimerix — Investor Presentation (February 2022)
25 slides from Dimerix's investor presentation, Feb 24, 2022
Slide 1: Investor Presentation February 2022
@ Dimerix (ASX:DXB) Investor Presentation February 2022 Authorised for lodgment by the Board of the Company
Slide 2: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different fro
Slide 3: About Dimerix
About Dimerix Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on developing new therapies to treat inflammatory causes of kidney and respiratory disease Advancing three ; rs % Phase 3 clinical studies i Wh w Demonstrated
Slide 4: Share price and top shareholders
For personal use only Share price Top shareholders
Slide 5: Development pipeline
Development pipeline Program Indication Preclinical Phase 1 Phase 2 Phase 3 Key milestones . Phase 2a demonstrated encouraging efficacy & safety’; Phase 3 underway (ac) Glomerular Sclerosis CF with regulatory &/or ethics authorisation in multiple countries’, recruitment of 1* patients planned Q1 22,
Slide 6: Pro-inflammatory chemokines
For personal use only Pro-inflammatory chemokines
Slide 7: Kidney Disease Development Overview
Kidney Disease Development Overview
Slide 8: FSGS: unmet need and market potential
FSGS: unmet need and market potential meXer]| =some 50% Segmental = sections of patients with Glomerulo = of the kidney filtering units FSGS will Sclerosis = are scarred Progress a kidney failure 20,000 FSGS patients in US have kidney failure “4000 FSGS patients in US receive a 2x more common “40,00
Slide 9: FSGS phase 3 study design
FSGS phase 3 study design nt ACTIAN3 A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes FSGS CLINICAL STUDY of DMX-200 in patients with primary FSGS receiving an ARB ARB stabilisation Treatment period weeks -6 -1 0 35 104 I il ! 6 oN 2 DMX-200 ® oI 2£f 2 2] = BI 3 a
Slide 10: FSGS phase 3 study locations
FSGS phase 3 study locations Global study with “70 sites in 12 countries: Count Regulatory and/or ethics y approval to proceed ACTIGNS Australia v Argentina v FSGS CLINICAL STUDY Brazil Denmark v France v A randomised, double-blind, multi-centre, placebo- Hong Kong controlled study of renal outcomes
Slide 11: Patent protection and exclusivity
For personal use only 1. If patent applications are granted: PCT/AU2022/050013; 2. DMX-200 is a New Chemical Entity (NCE): an active moiety not approved before which can attract exclusivity periods in various territories 3. Granted patents US9,314,450; US10,058,555; US10,525,038; CN2012800046165; CA
Slide 12: COVID-19 Respiratory Complications
COVID-19 Respiratory Complications
Slide 13: COVID-19 and pneumonia market potential
COVID-19 and pneumonia US$17 billion pre-COVID: Pneumonia responsible for US$17 billion in healthcare costs each year in the us! 3 million deaths annually caused by lower respiratory tract infections pre-COVID* hh 4.5 million: COVID-19: caused 219 million cases globally to date, resulting in >4.5 mi
Slide 14: Potential benefits of DMX-200
Potential benefits of DMX-200 Antiviral medications: Typically effective at preventing damage caused by a virus when administered days of infecti when many are asymptomatic 1. Brown L etal (2021) Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol
Slide 15: Two Phase 2 studies in COVID-19 patients
Two Phase 3 studies in COVID-19 patients ss REMAP-CAP REMAP-CAP: COVID-19 pneumonia in ICU » >750 patients recruited to the study domain * WHO endorsed study * Primary endpoint = 21 day mortality Funded by European Union through H2020 “Rapid European COVID-19 Emergency Research response” (RECOVER) p
Slide 16: Additional longer term propositions
Additional longer term propositions
Slide 17: Additional asset value propositions
Additional asset value propositions Longer term opportunities Diversifying DMX-200 risk and Diabetic Kidney ferent Disease Uiee revenue Addressable market US$1.1 billion* Key driver is the rise in diabetes global incidence @ Dimerix 2017 IQVIA ARB prescription and pricing data; DMX-700 Chronic Obstr
Slide 18: For personal use only
For personal use only
Slide 19: For personal use only
For personal use only ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ❑ ❑ ❑ ❑ ❑ ❑
Slide 20: Dimerix
Dimerix A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. Advancing three Phase 3 opportunities Well positioned to deliver against strategic plan Dimerix HQ
Slide 21: Appendix
a@)\_ or personal use ‘= 7 _4 Dimerix, Appendix
Slide 22: Phase 2a DMX-200-202 (ACTION for FSGS) study
For personal use only Phase 2a DMX-200-202 (ACTION for FSGS): Phase 2a, Double-blind, Randomised, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of DMX-200 in Patients with Primary Focal Segmental Glomerulosclerosis who are Receiving Irbesartan • Primary endpoint: safety. Sec
Slide 23: DMX-200 inflammatory biomarker
DMX-200 inflammatory biomarker Average baseline MCP-1 versus average baseline proteinuria Dimerix Baseline uMCR (ng/mmol) 2 B =} S 1 Ny 8 L o o T T T 200 400 600 800 Baseline PCR (mg/mmol) 1 1000 DMX-200 Phase 2 study confirmed high MCP-1 correlates to high proteinuria in FSGS patients uMCR= Urinary
Slide 24: Change in PCR ratio: DMX-200 vs placebo
Geometric mean difference -17% For personal use only (95% CI -43 to +20; p0.25) 0 Change in PCR ratio (%) -10 -20 -30 -40 -50 PPG Placebo DMX-200 • • ▪ ▪
Slide 25: DMX-200 treatment group met primary and secondary endpoints
DMX-200 treatment group met primary and secondary endpoints Average reduction in proteinuria after 16 weeks treatment on DMX-200 versus placebo compared [app erloleel-vanrelaringclecveMel|-t-lmlet-tal-liimicod oy-le(-1a M1 gers) to standard of care alone in FSGS patients! 0.0% 2 2 5.0% £8 as <y £3 S